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The role of PEF monitoring in the diagnosis and monitoring of
asthma
T
he Wright peak expiratory flow
meter was introduced in 19591 and
provided a portable piece of equip-
ment for assessing some aspects of lung
function in the ambulatory care setting.
The original device has been supplanted
by the mini Wright peak flow meter
(and a range of other devices) which
have become relatively cheap but are
reasonably reliable for home monitor-
ing.2
So, with an available device for
measuring peak expiratory flow (PEF),
what is its role in the 21st century? PEF
reflects a range of physiological char-
acteristics of the lungs, airways, and
neuromuscular characteristics of indivi-
duals. These include lung elastic recoil,
large airway calibre, lung volume, effort,
and neuromuscular integrity.3 The
reflection of airway calibre makes the
PEF meter suitable for measuring varia-
tion in PEF over time to provide support
for:
N confirmation of the diagnosis of
asthma;
N diagnosis of occupational asthma;
N monitoring variation in PEF over
time;
N identification of asthma control;
N use in self-management of asthma by
patients via written action plans
based on changes in PEF.
We must note that the PEF is not the
same as the forced expiratory volume in
1 second (FEV1)—either in repeatability
or in the interpretation of what it is
measuring—and they cannot necessa-
rily be interchanged.4 An earlier trend to
suggest regular PEF monitoring for
many asthmatics has been modified as
issues of balancing adherence versus
need versus usefulness have been recog-
nised. Regular PEF monitoring in
asthma does remain relevant in parti-
cular situations such as monitoring of
poor perceivers of symptoms.5
The report by Reddel et al6 in this issue
of Thorax highlights a further advance in
the evidence for the use of PEF mon-
itoring. The identification of best PEF
provides a target for individual asthma
patients and treating health profes-
sionals to enable the development of
action plans and for the assessment of
asthma control. The finding by Reddel et
al6 that, on average, the best PEF can be
determined using high dose inhaled
corticosteroids for 3 weeks from an
unstable asthma state with twice daily
PEF measurements therefore provides
helpful information for the treating
doctor. It is noteworthy that the time
frame moves out to approximately
8 weeks if a single daily morning
measurement of PEF is done—possibly
a reflection of the number of measure-
ments, but the time for drug effect
cannot be dismissed.
Can we translate these data to our
usual practice? The answer has to be a
cautious yes because of (a) the use of
electronic spirometers in the study and
(b) the involvement of the patients in a
clinical trial. Neither of these conditions
is available to the usual asthma patients.
However, the concept of an average of
3 weeks of inhaled budesonide
(1600 mg) or its equivalent to achieve
best PEF with twice daily readings
provides a sound basis for the therapeu-
tic trial which may become more impor-
tant in the diagnosis as well as the
management of asthma. Daily morning
PEF monitoring in the study by Reddel
et al6 showed that an average of 8 weeks
of high dose inhaled corticosteroid
treatment study is needed to obtain
the best PEF across a population of at
least moderate and even severe asthma.
We can therefore take away two mes-
sages from this study. The first is that, in
reliable morning PEF data, a period of
8 weeks of high dose inhaled corticos-
teroids results in identification of the
best PEF function for individuals on
average. The second message is that, on
average, 8 weeks of treatment with up
to 1600 mg budesonide daily or its
equivalent is a reasonable therapeutic
trial for diagnosis or identifying best
function in symptomatic patients. This
is an important concept because the
therapeutic trial over a period of time to
confirm a diagnosis of asthma is likely
to become more important, given the
recognised reduced usefulness of a
single bronchodilator response in either
predicting future management or in
diagnosis.7
Other data have supported an 8 week
time frame for maximising the major
airway effects of inhaled corticoster-
oids.8 9 Providing we are not absolute
in our application of average data, the
study by Reddel et al can be usefully
applied in day to day clinical practice
and provides a guide to an appropriate
level of inhaled corticosteroid for a
treatment trial. The study has not
necessarily identified the lowest dose,
but the time frame of 8 weeks for daily
morning PEF measurements and the
dose equivalent of 1600 mg inhaled
budesonide seems to provide a reason-
able baseline for clinical practice. It is
possible that a lower dose of inhaled
corticosteroids may be effective in a
therapeutic trial, and this needs to be
tested despite a recent meta-analysis.10
The combination of an inhaled cortico-
steroid with a long acting b agonist is
likely to have a place in the future
therapeutic trial.
A further question to be answered for
treatment trials is whether the PEF
(maximum) before and at the comple-
tion of a treatment trial is compared or
whether it is the change in PEF varia-
tion. In children, questions have been
raised about PEF monitoring missing
important changes.11 We therefore must
remember that much of our evidence
base relates to averages, and in the
clinical setting we should individualise
our assessments and management. The
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Three papers published in this issue of Thorax add some further
twists to our understanding of the microbiology of CF
T
he link between dysfunction of the
CFTR protein and the pathophysiol-
ogy of lung disease in cystic fibrosis
(CF) has recently become clearer.
Abnormal sodium and chloride ion
transport in respiratory epithelial cells
results in depletion of airways surface
liquid volume, delayed mucus transport,
and impaired bacterial clearance.1 2 This
initiates airways inflammatory res-
ponses leading, ultimately, to lung
injury in CF. The most important pre-
dictors of poor outcome are chronic
infection with Pseudomonas aeruginosa
and Burkholderia cepacia complex and




Pulmonary infection in CF is charac-
terised by a narrow spectrum of micro-
organisms and is dominated in older
patients by P aeruginosa. This organism
and other related Gram-negative bac-
teria adapt to the conditions found in
airways mucus and establish biofilms
which allow chronic infection to be
established.6 Recent studies suggest that
this microenvironment is relatively
hypoxic and this creates a hospitable
environment for P aeruginosa which,
when exposed to low oxygen concentra-
tions, increases alginate formation
which assists in the development of
micro-colonies within a biofilm.7 The
biofilm protects P aeruginosa from host
defence, bacterial clearance mechan-
isms, and antibiotics. In addition, bac-
terial adherence to mucus is increased in
CF which may also contribute to diffi-
culties in clearing it from the airways.7
The source of early P aeruginosa infec-
tion is either the environment or other
patients with CF. Aggressive treatment
of early infection with this organism can
frequently eliminate it for some years
but, by the end of the second decade,
over 80% of patients with CF have
chronic Pseudomonas aeruginosa infec-
tion.8 9
Recent studies have shown that, in
some CF centres, clonal spread of P
aeruginosa can occur.10 11 This is some-
times associated with a multiply resis-
tant antibiotic profile, although not
necessarily so. In general, antibiotic
resistance is increasing in the CF popu-
lation, particularly against the most
commonly used antibiotic, ceftazidime.
This probably represents antibiotic pres-
sure and the ability of P aeruginosa to
mutate because of its rather large
genome. Antibiotics may select hyper-
mutable strains which can maintain and
possibly pass on resistance.12 A close link
between transmissibility, antibiotic
resistance, and patient survival has not
been unequivocally demonstrated.
Transmissibility of resistant strains of
Pseudomonas is intuitively something
that should be avoided. However,
further studies are awaited to determine
if this has an important clinical outcome
for patients with CF.
In addition to P aeruginosa, a number
of other Gram-negative bacteria have
emerged as important potential patho-
gens in CF lung disease. Burkholderia
cepacia complex, Stenotrophomonas malto-
philia, and Achromobacter (Alkaligines)
xyloxidans are the most important and,
although probably environmental in
origin, cause chronic airways infection
in patients with CF. These organisms,
although phylogenetically unrelated, are
usually all multiply resistant to anti-
biotics.
Burkholderia species
Burkholderia cepacia complex was the
first of these organisms to be recognised
and is the most pathogenic. A number
of epidemics in CF centres have been
described. Infection with this group of
organisms is associated with an accel-
eration in the decline in FEV1 and
increased morbidity and reduced survi-
val.4 13–15 The taxonomy of this genus has
recently been fully elucidated and nine
groups have been speciated.16 All these
species of Burkholderia have been
described in patients with CF but the
predominant are B multivorans and B
cenocepacia. B multivorans is a less
common cause of infection than B
cenocepacia.17 A number of studies have
suggested that B multivorans is generally
less virulent that B cenocepacia. However,
B multivorans has been associated with
‘‘cepacia syndrome’’ and epidemic
spread.
In a study reported in this issue of
Thorax from a single centre, patients
with B multivorans and B cenocepacia and
P aeruginosa were compared.18 Patients
with B multivorans had a lower mortality
than those infected with B cenocepacia. B
multivorans had a similar clinical impact
to chronic infection with P aeruginosa.
This finding supports studies from other
centres. No significant differences in
morbidity were found, although others
have shown an accelerated decline in
FEV1.
4 19 This study also confirms pre-
vious studies which reported mostly
unique strains in patients with B multi-
vorans infection, suggesting that this
organism is usually acquired from the
environment rather than by patient to
patient transmission. Patients with B
multivorans should therefore not be
exposed to those with B cenocepacia,
which is strongly associated with
patient to patient transmission and is
more virulent. This study emphasises
the much greater virulence of B cenoce-
pacia than P aeruginosa and supports the
need for careful infection control mea-
sures to minimise the risk of cross
infection.
In another paper published in this
issue of Thorax, Coenye and colleagues
describe a clonal strain of B cenocepacia
not previously identified in Europe.20
Over the past few years it has become
clear that B cenocepacia is made up of
clonal subspecies and there may be
differences in virulence and transmissi-
bility between clones. The most com-
mon subspecies in the UK is the ET12
group (Electrophoresis Type 12), first
described in Edinburgh and associated
with most of the severe epidemics in the
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UK and Canada. This strain is very
virulent and is associated with ‘‘cepacia
syndrome’’. A new strain, PHDC, has
now been described and has affected
patients in a number of centres around
Europe. No clinical data are yet available
with regard to its virulence in patients
from whom this organism has been
isolated, but it is of considerable con-
cern that there is evidence of clonal
spread between continents. The major-
ity of samples were from patients with
CF but one was from a urine sample
from 1964. This is an unusual finding
which is unexplained. Further studies
will be required to determine the
clinical relevance of this and possibly
other clonal strains of B cepacia
complex organisms. It is possible that
a number of other clonal variants of
B cenocepacia and other species are pre-
sent in CF clinics and that there may be
differences in the clinical impact of
these clones.
This new finding emphasises the need
for careful microbiological surveillance
of patients with CF. Phenotypic identi-
fication of B cepacia is difficult. It is
almost always pan-resistant to com-
monly used antipseudomonal antibio-
tics and this cannot be used for typing
purposes. There are now specific pheno-
typic tests for identifying B cepacia
complex species, but these are not
helpful in identifying clonal subgroups
such as ET12 or PHDC which require
diagnosis at a molecular level using
various DNA typing methods. It is very
important that all CF centres should
have access to such surveillance. This is
available from two laboratories in the
UK and reference laboratories in the US
and in Europe.
Stenotrophomonas maltophilia
In a third paper published in this issue
of Thorax, Goss et al provide further data
on the virulence of Stenotrophomonas
maltophilia.21 This organism is multiply
resistant but, in contrast to B cepacia
complex, it appears to have a compara-
tively benign effect on the CF lung. This
is the second study of S maltophilia
published by this group from the
North American database and reports
morbidity on a large cohort of people
infected with the organism. The pre-
vious study showed that S maltophilia
infection is not associated with an
increase in short term mortality.22 Their
data do not tell us whether this organ-
ism is transmissible, although this
seems in general to be unlikely.
However, one centre is reported to have
a case rate of 38% which raises the
possibility of cross infection in some
situations. Their data suggest that the
organism, although multiply resistant to
antibiotics, is not associated with an
acceleration in the decline in FEV1.
Those with S maltophilia infection had
a lower starting FEV1 before infection,
suggesting that poorer lung function
predisposes to acquisition of this organ-
ism. The majority (66%) were co-
infected with P aeruginosa, but it is not
clear if this was of any clinical signifi-
cance.
Significance of these findings
The microbiology of CF can be very
confusing. The nomenclature is complex
and organisms change their names, and
there are few generalisations that can be
made across the different species. The
studies published in this issue of Thorax
add some further twists. A hierarchy of
virulence of Gram-negative organisms is
emerging. S maltophilia seems to be the
most benign followed by P aeruginosa. B
multivorans is similar to P aeruginosa but
B cenocepacia is the most virulent by a
significant degree. There may be impor-
tant differences in the virulence of
subspecies of B cenocepacia but this
requires further epidemiological study.
It is not yet clear how other organisms
which cause chronic infection in CF
such as A xyloxidans or Pandorea species
fit into this hierarchy.
These organisms are generally multi-
ply antibiotic resistant, but this by itself
does not imply transmissibility or viru-
lence. There must be other virulence
factors associated with specific organ-
isms or possibly host-bacteria interac-
tions which ultimately result in lung
injury. These studies further emphasise
the importance of surveillance of
patients with CF to determine their
airway microbiology. Careful infection
control policies are required to prevent
acquisition of the more problematic
organisms such as B cenocepacia. These
should be tailored to the epidemiology
of the individual centre and based on
accurate identification and typing of
the bacteria. There is a need for further
understanding of how infection and
inflammation result in airway damage,
hopefully to find ways of circumventing
the lung damage which ultimately
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Sodium hyperabsorption may be a key therapeutic target in CF
C
ystic fibrosis (CF) lung disease is
characterised by thick viscid air-
way secretions, the development
of progressive airways obstruction and
bronchiectasis, and colonisation with
specific bacteria, notably Pseudomonas
aeruginosa.1 Although the precise patho-
genic pathways in CF are still debated
(see below), airway epithelial ion trans-
port has been known to be defective in
CF for two decades. This can be assessed
in the airway in vivo by measuring
potential difference (PD)—that is, the
voltage generated across an electrically
tight epithelium by the active transport
of charged sodium and chloride ions.2 In
patients with CF the magnitude of
sodium absorption across airway epithe-
lia and the response to the sodium
channel blocker amiloride are substan-
tially increased compared with normal
subjects, coupled with an inability to
secrete chloride ions.3 In the 1990s the
putative gene (the cystic fibrosis trans-
membrane conductance regulator
(CFTR) gene) was cloned4 and the
affected protein was identified as a
gated chloride channel,5 supporting the
hypothesis that CF is linked to abnormal
transepithelial ion transport.
Despite this clear link between abnor-
mal ion transport and CF, the pathogen-
esis of lung disease in CF is complex,
and much effort has been expended
trying to elucidate the pathways
involved in the development of airways
disease. One hypothesis suggests that
lung disease in CF develops in large part
because of the deranged ion transport,
resulting in a reduction in airway sur-
face liquid volume and compromised
mucociliary clearance.6 These abnormal
mechanisms set up a cycle of retained
airway secretions, accumulation of
mucus with infection and inflammation
in the airways, ultimately leading to
airway destruction, respiratory failure,
and death from lung disease.
Recent in vitro studies on airway cell
cultures grown to confluence with an
air/liquid interface have yielded further
insights into the impact of the CF
ion transport defect on airway defence
mechanisms.7 In the absence of CFTR,
sodium absorption (through the
epithelial sodium channel (ENaC)) is
upregulated. Subsequent dehydration
of the airway surface liquid results in
abolition of normal ciliary function.
Thus, sodium (and fluid) absorption
appears to dominate the normal ‘‘steady
state’’ in the airway; however, recent
data have shown that, under certain
circumstances, airway epithelium can
shift its phenotype and chloride (and
fluid) secretion becomes predominant.8
In CF airway cultures this ability to
shift to a secretory phenotype is
compromised.
Which ion transport abnormality is
most important in CF lung disease?
So which of these abnormalities—upre-
gulation of basal fluid absorption or an
inability to switch efficiently to a secre-
tory phenotype—is most important for
the development of CF lung disease?
Both mechanisms could theoretically
result in similar reductions in airway
surface liquid volume with the resulting
impact on mucociliary transport. This
question is important, since potential
therapeutic strategies currently target
both loops of the cascade, for example,
with sodium channel blockers and
chloride secretagogues.9 10 It may be that
both the sodium and chloride ion trans-
port defects have a role (a double hit) in
the pathogenesis of CF; however, mur-
ine models suggest that sodium hyper-
absorption may be more important.
In the 1990s a number of cftr knock-
out mice were generated.11–13 These mice
have a form of gastrointestinal disease
but no overt lung disease. This has been
explained by chloride secretion through
alternative channels in the airway.14
Nasal PD in these ‘‘CF mice’’ is raised,
as in humans with CF and consistent
with sodium hyperabsorption; however,
surprisingly, there is no increased PD in
the lower airway.15
A major development has been the
recent generation of a transgenic mouse
with overexpression of the b subunit of
the ENaC gene in the airways (driven by
a lung specific promoter), but with
normal cftr expression and function.16
These mice have an increased magni-
tude of PD throughout the airway,
consistent with sodium hyperabsorp-
tion, and develop early respiratory dis-
tress with a significant number dying in
the first month of life. Investigations
reveal depletion of airway surface liquid
and mucus accumulation with reduced
airway and bacterial clearance. The
striking similarity to human CF disease
provides convincing evidence that
sodium hyperabsorption may be a pri-
mary determinant of CF lung disease.
Does the extent of ion transport
abnormality in the airway
determine the severity of CF lung
disease?
Many groups have looked for a link
between the degree of abnormality of
airway ion transport (as determined by
the nasal PD) and disease severity.
Some have suggested relationships
between the respiratory condition and
sodium hyperabsorption (as determined
by basal PD/response to amiloride),17
and others with chloride secretion (as
determined by the change in PD under
specific conditions—that is, following
perfusion of a solution with chloride
ions replaced by gluconate with a b
agonist such as isoprenaline).18 These
different results probably reflect small
numbers and differing techniques. A
European study reduced the confound-
ing variables of environment and geno-
type by examining twins and siblings
homozygous for DF508.19 A weak rela-
tionship between respiratory disease
and chloride secretion was demon-
strated (concordant sibling pairs with
mild disease had a small but signifi-
cantly increased level of chloride secre-
tion compared with pairs with severe
disease). Subsequent groups have not
been able to identify a link between
respiratory phenotype and chloride
secretion.20 21
In this issue of Thorax Fajac and
colleagues provide data which add to
this debate.22 Using nasal PD, they
measured ion transport in 79 adult
patients with CF of varying severity
and related PD outcomes to pancreatic
status (pancreatic sufficient (n=17) or
pancreatic insufficient (n=62)) and
lung function (forced expiratory volume
in 1 second (FEV1) .50% predicted
(n=49) or ,50% predicted (n=30)).
All patients with CF had diagnostic
sweat chloride levels except for four
patients with mild genetic mutations
(73/79 had two recognised CFTR muta-
tions). At baseline, patients with CF
either had a raised basal PD with
increased sensitivity to amiloride (typi-
cal of CF) and/or a lack of response to
perfusion with a low chloride solution
with isoprenaline. They found a weak
relationship between the severity of
lung disease (as determined by FEV1)
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and increased sodium transport (as
determined by basal PD and response
of that PD to amiloride). With a
univariate analysis, basal PD was
slightly higher in subjects with severe
lung disease (mean 254 mV) than in
those with milder lung disease (mean
245 mV). The reduction with amiloride
was also greater in the severe group
although, in a multivariate analysis
including chronic infection with P aeru-
ginosa, the relationship between lung
function and basal PD disappeared but
remained for lung function and amilor-
ide sensitivity (odds ratio 3.7). There
was no relationship between FEV1 and
chloride secretion (+2 mV in severe lung
disease, +1 mV in mild lung disease).
Where does this leave us in our
understanding of the impact of ion
transport on CF lung disease?
The bottom line is that, if a true
relationship between ion transport (as
measured by nasal PD) and the severity
of respiratory disease exists, it is likely
to be weak. These data are consistent
with the notion of a ‘‘point of no
return’’—that is, the ion transport
abnormality provides the setting for CF
lung disease early in life but, once
established, other factors such as non-
CFTR gene modifiers, the response of the
innate immune system, mucus secretory
control mechanisms, or environmental
factors are more important in determin-
ing disease severity.23
Is this concept important? Certainly;
nasal PD has frequently been employed
as a surrogate outcome measure for
‘‘proof of principle’’ trials of new treat-
ments.24 If fundamental treatments are
to work, these data suggest that early
intervention is necessary as other factors
may have a more profound influence on
the eventual severity of lung disease. If
ion transport is to be used as a surrogate
outcome for fundamental treatments,
then the data from murine studies
suggest that correction of sodium hyper-
absorption is the least required to halt
the development of CF lung disease
rather than correction of the chloride
secretory defect alone.25
Although Fajac and colleagues did not
find a strong relationship between ion
transport and respiratory disease, they
did find that pancreatic sufficient
patients are significantly more likely to
have evidence of chloride secretion in
their nasal airway.22 If nasal PD reflects
ion transport elsewhere, such as in the
pancreatic ducts, then this is an impor-
tant observation in terms of the patho-
genesis of CF pancreatic disease.
Fromapractical point of view, this find-
ing has a bearing on the interpretation of
nasal PD measurement when used to
determine a diagnosis in people with
atypical clinical features and equivocal
sweat test results. The combination of
a raised magnitude of basal PD and a
lack of cftr-mediated chloride response
is strong supportive evidence of a CF
diagnosis, with the latter having been
advocated as the most reliable compo-
nent of the nasal PD tracing for making
a diagnosis of CF.26 27 However, groups
have presented data demonstrating sig-
nificant chloride secretion in some pati-
ents with ‘‘classic’’ CF.17 21 Therefore, in
the presence of a high magnitude of
basal PD (.40 mV), the finding of
chloride secretion does not negate a
diagnosis of CF; indeed, the data of
Fajac et al suggest that, in patients who
are pancreatic sufficient, this may reg-
ularly be the case.
From a treatment standpoint, it seems
logical to focus efforts on modulating
the sodium channel to restore volume to
the airway surface liquid, improve
mucociliary clearance, and prevent the
first step towards CF lung disease early
in life. A balance may be required
between agents that stimulate chloride
secretion and agents that block sodium
absorption, in order to restore airway
surface liquid volume and achieve ade-
quate airway clearance mechanisms in
CF. However, at present, the weight of
evidence suggests that sodium hyper-
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Failure of empirical treatment for CAP
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Identifying failure of empirical
treatment for pneumonia: vigilance and
common sense
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Some progress in identifying the risk factors associated with
treatment failure in CAP
I
n patients with community acquired
pneumonia (CAP), clinical and
radiological features at the time of
presentation do not predict the micro-
biological aetiology with any certainty.1
Initial treatment is therefore usually
empirical and directed by the severity
of the illness at the time of presentation.
A large number of studies have been
conducted over the last 10 years to
determine prognostic factors in CAP. In
turn, clinical prediction rules based on a
number of key prognostic factors have
been developed, such as the pneumonia
severity index (PSI) and the CURB-65
score, and incorporated into CAP man-
agement guidelines.2–6 Most of these
CAP severity studies, and the resulting
prediction rules, use mortality as the
main outcome measure. However, mor-
tality is not the only clinically important
outcome. In this issue of Thorax,
Mene´ndez and colleagues report on a
large observational study of the risk
factors related to failure of initial
empirical treatment for CAP.7
The definition of treatment failure
adopted was complex and based on (a)
the time from admission (less than or
more than 72 hours corresponding to
‘‘early’’ and ‘‘late’’ treatment failure)
and (b) the occurrence of clinical fea-
tures such as ‘‘haemodynamic instabil-
ity’’, ‘‘the appearance or impairment of
respiratory failure’’, and ‘‘radiographic
progression’’. While pragmatic, these
features were not rigorously defined,
thus making it difficult to compare the
results of this study with other research.
Also, the ordering of repeat chest radio-
graphs, a key element in the definition,
was left to the discretion of the attend-
ing physician, so introducing a potential
bias into the detection of treatment
failure. Accepting these limitations, 15%
of a cohort of 1424 hospitalised patients
experienced treatment failure. These
patients had a longer mean length of
hospital stay (18.5 days v 9.4 days) and
increased mortality (25% v 2%). Most of
the treatment failures occurred in the
first 72 hours.
Initial treatment with fluoroquino-
lones was found to be associated with
a lower risk of treatment failure but not
with in-hospital mortality. The research-
ers offer a good discussion on the
possible explanations for this finding.
The high prevalence of penicillin resis-
tant Streptococcus pneumoniae (,30% of
isolates) in the study country (Spain)8 9
compared with the prevalence of fluoro-
quinolone resistant strains (,1%) may
indeed be relevant.10 The excellent cov-
erage of atypical pathogens by the
fluoroquinolones may also be impor-
tant. Patients in the study were treated
according to prevailing Spanish guide-
lines. This means that hospitalised non-
ICU patients could be treated with
either a third generation cephalosporin
or co-amoxiclav with or without a
macrolide, or monotherapy with a
fluoroquinolone. Certainly those pati-
ents treated with only a third generation
cephalosporin or co-amoxiclav (29% of
cases) would not have had coverage
for infection by an atypical pathogen
compared with those treated with a
fluoroquinolone
Retrospective studies have suggested
that treatment with b-lactam drugs in
combination with a macrolide or a
quinolone is associated with lower
mortality in CAP compared with other
antibiotic regimens.11 Unfortunately, the
difficulty with these observational stu-
dies is the inability to correct adequately
for confounding factors that might have
influenced the initial choice of antibio-
tic. Conversely, the emergence of fluoro-
quinolone resistant pathogens in areas
with a high consumption of fluoroqui-
nolones is a very real problem and
cautions against their overenthusiastic
use.12 More work is needed to clarify the
advantages of the fluoroquinolones in
comparison with other antibiotic regi-
mens in the empirical treatment of CAP.
The following risk factors were found
by Mene´ndez and colleagues to be
independently associated with treat-
ment failure: the PSI prediction rule
for risk of mortality (the PSI categorises
patients into risk classes I–V corre-
sponding to ascending risk of mortal-
ity), leucopenia (,4000 cell/mm3), liver
failure, and the presence of adverse
chest radiographic features on admis-
sion (specifically, the presence of pleural
effusions (OR 2.6), multilobar involve-
ment (OR 2.2), or cavitation (OR 5.2)).
Each of these risk factors (except lung
cavitation) has previously been reported
to be independently associated with
mortality in CAP.13 14 Indeed, the pre-
sence of liver disease and a pleural effu-
sion are two of the 20 variables included
in the PSI prediction rule. This is not
altogether surprising since treatment
failure was itself associated with mor-
tality, and no clinical prediction rule can
be expected to fully account for all the
recognised features of disease severity.
Impact on clinical management
How then might these findings enhance
our current management of CAP, if at
all? Their main contribution is going to
be in the management of patients at low
risk of mortality. With regard to the
decision to admit to hospital, current
recommendations are based on an
assessment of mortality risk, social
circumstances, and the stability of co-
morbid illnesses. In recognition of the
limitations of assessing disease severity
solely according to risk of mortality, all
guidelines underline the importance of
clinical judgement.4 15 The study by
Mene´ndez and colleagues is helpful in
highlighting the additional risk factors
associated with failure of empirical
treatment (such as adverse chest radio-
graphic features) that should be taken
into account in patients identified as
being at low risk of mortality according
to the PSI. However, how these patients
should best be managed is not known.
Patients at risk of treatment failure may
still be suitable for ambulatory care
provided adequate early outpatient fol-
low up is arranged. Alternatively, they
may require hospital admission.16
Awareness of the expected time
course of clinical resolution allows
timely detection of treatment failure.
Halm and colleagues have shown that
the median time to clinical stability is
2 days for heart rate ((100/min) and
systolic blood pressure (>90 mm Hg)
and 3 days for respiratory rate ((24/
min), oxygen saturation (>90%), and
temperature ((37.2 C˚).17 Measurement
of theC-reactiveprotein (CRP) level is also
helpful because a CRP level that does not
fall by 50% within 4 days of admission is
suggestive of treatment failure.18 19
What to do once treatment failure
is recognised is not well studied.
Repeat and supplementary microbio-
logical investigations are generally
recommended in order to detect new,
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resistant, or nosocomial infections.
Bronchoscopy yields a diagnosis in up
to 41% of patients.20 One study found it
to be beneficial mainly in non-smoking
patients aged less than 55 years with
multilobar infiltrates.21
Where do we go from here? Further
work using robust and reproducible
definitions for treatment failure is
required to confirm the findings of
Mene´ndez and colleagues. The use of a
different prediction rule to adjust for
risk of mortality—for example, CURB-
65 instead of PSI—may result in the
identification of different risk factors for
treatment failure. Most importantly, the
optimal management of patients at risk
of treatment failure and how it might
differ from usual management needs to
be determined, ideally through inter-
vention studies with clinically relevant
end points.
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What happens to patients with
respiratory disease when they fly?
R K Coker, M R Partridge
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Updated guidelines now available but more research is needed
into the safety of air travel for those with respiratory disease
D
espite current concerns about ter-
rorism, commercial air travel
remains a common mode of travel
for millions. It has been estimated that a
single major UK airline carries over 30
million passengers each year. There are
no data available to indicate how many
passengers flying on commercial aircraft
have respiratory disease, but as far back
as 1974 it was estimated that around
5% of passengers were ambulatory
patients. As the average age of western
populations continues to rise, so does
the propensity for passengers to have
some form of medical condition. In
addition, flights are getting longer and
aircraft bigger. The new Airbus 380, for
example, will carry around 600 passen-
gers for up to and in some cases
exceeding 20 hours.
Air travel is in general safe, even for
those with medical conditions, and
there are no established methods for
determining morbidity associated with
air travel. Nevertheless, available airline
data consistently record around 10% of
in-flight medical emergencies as being
respiratory in nature, with approxi-
mately one third attributed to asthma.
Medaire, a North American company
offering radio link emergency medical
assistance to commercial aircraft, has
published figures for 2002 which show
that respiratory problems are the third
most common cause of in-flight medical
emergency (A Hawkins, Medaire, perso-
nal communication). Respiratory pro-
blems are also the third most common
cause of medical diversion after cardiac
and neurological events (including syn-
cope), accounting for 9% of diversions.
In 2002 Medaire recorded 414 diver-
sions, 206 advised by Medaire and 208
initiated by the pilot. In 2004 British
Airways estimate the cost of a diversion
at around £100 000 (J150 000,
US$185 000) (M Popplestone, British
Airways, personal communication).
This includes hotel accommodation for
passengers and staff, maintenance costs
and landing fees. In addition, there is
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knock-on disruption to the airline’s
schedule and there are safety concerns
about an enforced landing at an un-
familiar airport.
Commercial aircraft routinely fly at
around 38 000 ft and are pressurised to
a relatively modest intermediate cabin
altitude not exceeding 8000 ft
(2438 m). The reduced partial pressure
of oxygen at this altitude is equivalent
to breathing 15% oxygen and will cause
the arterial oxygen tension (PaO2) of a
healthy passenger to fall to between 7.0
and 8.5 kPa. The effects usually go
unnoticed. However, exposure to this
altitude may worsen hypoxaemia in
patients with lung disease, especially if
the subject is already hypoxaemic at sea
level. Other factors to be taken into
consideration include immobility pre-
disposing to venous thromboembolism,
an increase in gas volumes, reduced
humidity, and increased potential for
transmission of infection through pro-
mixity of seating arrangements.
In 2002 the British Thoracic Society
(BTS) published recommendations for
assessing passengers with respiratory
disease planning air travel.1 These were
the first UK recommendations on air
travel in the context of lung disease and,
in contrast to existing disease-specific
North American and European guide-
lines, considered a wide range of
respiratory disorders. A patient informa-
tion leaflet and summary for primary
care physicians were published along-
side the recommendations on the BTS
and British Lung Foundation websites
(www.brit-thoracic.org.uk and www.
britishlungfoundation.org). It was
recognised at the time that the BTS
recommendations represented a consen-
sus statement based on expert advice,
with little solid evidence on which to
base formal guidelines.
Two years on, the BTS flight recom-
mendations have been updated with
available evidence and published on
the BTS website in September 2004.
The data remain relatively sparse, but
updated sections include reference to
the demise of Concorde and the intro-
duction of the Airbus 380, and a detailed
explanation of the effect of Boyle’s law
on gas expansion in relation to humidi-
fied gas. Changes have also been made
to the recommendations for pre-flight
assessment in children based on new
data from the Royal Brompton Hospital
in London. There is some new advice for
those travelling with oxygen. Some air-
lines now issue a Frequent Traveller’s
Medical Card to frequent flyers with
special medical needs, and this may be
of value to passengers in reducing the
paperwork required before each trip.
With regard to patients with asthma
and chronic obstructive pulmonary dis-
ease (COPD), from April 2004 a new law
requires all aircraft on flights to and
from the United States to carry broncho-
dilator inhalers as part of their medical
kit. A new study of children with
Down’s syndrome has drawn attention
to the fact that these patients probably
merit careful evaluation before air tra-
vel, and there is reference to two studies
of patients with diffuse parenchymal
lung disease. An entire new section has
been added on severe acute respiratory
syndrome (SARS) with a hyperlink to
the World Health Organisation site.
Importantly, review of the available
evidence has meant that the arbitrary
‘‘six week rule’’ has been discarded for
patients with pneumothorax. A delay of
just 1 week is recommended after the
chest radiograph shows complete reso-
lution, except in the case of a traumatic
pneumothorax (or thoracic surgery)
when a delay of 2 weeks is advised.
There is further evidence strengthening
the previous recommendations that low
molecular weight heparin may be of
benefit to travellers at high risk of
venous thromboembolism.
Taken together, however, with the
exception of the paediatric data there is
little new evidence to suggest a need for
radical change to the previous recom-
mendations. Most previous investiga-
tions into the effects of air travel on lung
disease have examined patients with
COPD, and the available controlled
studies involve relatively small numbers
with stable disease and no co-morbidity.
Simulated altitude did not generally
exceed 1 hour and these studies have
largely excluded additional stressors
such as exercise, dehydration, and sleep.
In 2002 the BTS Air Travel Working
Party highlighted the need for further
research and drew attention to those
areas where data are particularly lack-
ing. These included the predictive value
(or otherwise) of spirometry, regression
equations, hypoxic challenge, and walk
tests in different disease groups, and the
risk of air travel for patients with diffuse
parenchymal lung disease.
In this setting, the paper by Seccombe
et al2 published in this issue of Thorax is
especially welcome. The authors exam-
ined the effect of simulated cabin
altitude—both at rest and during a
50 metre walk test—on 15 subjects with
interstitial lung disease (ILD) and 10
subjects with COPD. All subjects
were clinically stable, able to walk
100 metres, and had resting PaO2 equal
to or above 9.3 kPa—well above the
level at which most physicians would
have concerns about potential complica-
tions from air travel. In both groups
PaO2 fell significantly from that at rest
on room air to that breathing 15%
oxygen at rest, and again to completion
of the walk test. Mean PaO2 fell to
5.5 kPa after exercise in the ILD group
and to 5.3 kPa after exercise in the
patients with COPD. Interestingly, 80%
of subjects had flown in the previous
5 years and 64% were unaware that
their oxygen levels might be lower when
flying.
These results suggest that resting PaO2
is a poor predictor of hypoxaemia under
simulated cabin altitude conditions.
They also highlight the need for further
research into predictors of hypoxaemia,
better patient education, and improved
methods for collecting data on passen-
gers who do experience health problems
while flying. The authors of this study
suggest that prospective evaluation of a
large number of patients with lung
disease who plan to fly may be of value.
The ongoing UK Flight Outcomes Study,
funded by the BTS and British Lung
Foundation, sets out to do this, and we
hope it will help to answer some of the
questions raised by this and other
studies. Meanwhile, further high calibre
laboratory research remains very wel-
come, together with more in-flight
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New evidence-based guidance on anti-TNF-a treatment is being
developed by the Joint Tuberculosis Committee of the BTS in
conjunction with the British Societies of Rheumatology and
Gastroenterology
A
nti-tumour necrosis factor (TNF)
treatment for rheumatoid arthri-
tis and Crohn’s disease has been
introduced over the last few years. Infli-
ximab (Remicade; Schering-Plough), a
humanised monoclonal antibody, is
licensed for the treatment of both
rheumatoid arthritis1 and Crohn’s dis-
ease,2 while etanercept (Enbrel; Wyeth
Laboratories), a fusion protein binding
free TNF-a using the soluble portion of
the TNFR-2 receptor,3 and adalimumab
(Humira; Abbott Laboratories), a fully
humanised monoclonal antibody,4 are
licensed for treating rheumatoid
arthritis. Post-marketing surveillance
in the USA5 has identified cases of
tuberculosis (TB) associated with inflix-
imab use and a smaller number with
etanercept. TB cases have also been
reported in association with adalimu-
mab (Humira prescribing information,
Abbott Laboratories, 2002). The cases
associated with infliximab occurred
within three cycles of treatment, with
a median of 12 weeks from commen-
cing treatment,5 and most were in
extrapulmonary sites.6 Calculations
have suggested that TB rates in patients
in the USA treated with infliximab or
etanercept are six times that of
untreated patients.7
The increase in active TB in associa-
tion with anti-TNF-a treatment has led
to a requirement for patient screening
for active and latent TB before anti-TNF
treatment is given. However, the screen-
ing—which the manufacturers suggest
should include tuberculin testing—
introduces further complications.
Firstly, in the study of infliximab,
Keane et al5 found that up to 79% of
patients were receiving immunosup-
pressive therapy before anti-TNF treat-
ment which would have precluded
effective skin testing for TB. Secondly,
in Europe, where the population may
have received prior BCG vaccination, the
interpretation of tuberculin tests is
further complicated. Thirdly, chemopro-
phylaxis or preventive treatment for TB
itself carries a risk—principally of drug
induced hepatitis—which increases
with age, varies with the chemoprophy-
laxis regimen, and can occasionally be
fatal.
Clearly, persons found to have active
TB or with evidence of previous TB
disease which has not been adequately
treated will need at least some anti-
tuberculosis treatment before anti-TNF
treatment can commence. However,
since the majority of patients will not
be assessable for prior TB infection by
skin testing, a judgement of the indivi-
dual risk of TB disease will have to be
made. Within the UK, and probably in
other developed countries, the indivi-
dual risk of TB can vary markedly. In the
UK the major determinants of risk are
age, ethnicity and—for those born out-
side the UK—the length of time since
first entry.8 For example, the annual risk
of disease can vary from 2/100 000 in a
white person aged 15–34 years to 593/
100 000 in a South Asian aged over
35 years who has been in the UK for less
than 5 years. The ‘‘individual risk’’
would then need to be multiplied by
five to allow for the additional effect of
anti-TNF treatment and this derived
figure would then have to be compared
with the risk of significant hepatitis
(level 3 or 4) from the proposed TB
chemoprophylaxis regimen, with at
least one regimen used in the USA
(rifampicin and pyrazinamide for
2 months) being too toxic for use.9 The
risk of chemoprophylaxis compared
with the chance of contracting TB will
therefore favour observation in some
individuals and TB chemoprophylaxis in
others. In future, gamma-interferon
production from whole blood and/or
stimulated lymphocytes10 may be able
to determine whether patients receiving
immunosuppressive treatment which
interferes with tuberculin skin testing
have been previously infected with TB,
but an individual assessment of the risk/
benefit ratio in such patients with
respect to chemoprophylaxis will still
be needed.
All these factors have led to many
requests for guidance in this area. The
Joint Tuberculosis Committee of the
British Thoracic Society, a subcommittee
of the Standards of Care Committee, is
developing practical evidence-based gui-
dance in conjunction with the British
Societies of Rheumatology and Gastro-
enterology. In order to meet the AGREE
criteria,11 however, this will take some
time. Initial draft proposals have been
posted on the members’ website for
comment. There are, however, some
concerns that this will be an additional
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